Menu
Recruiting NCT06441630

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

Phase III Interventional Essential Hypertension

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AD-227A, AD-227B, AD-227C, Placebo of AD-227B.
Who it may be relevant to
Registry conditions: Essential Hypertension. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension

Overview

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Detailed description

Essential Hypertension

Interventions

  • Drug AD-227A
    Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug AD-227B
    Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug AD-227C
    Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug Placebo of AD-227B
    Per Oral, 1 Tablet, Once a day for 8 weeks
  • Drug Placebo of AD-227C
    Per Oral, 1 Tablet, Once a day for 8 weeks

Primary outcome measures

  • Change in MSSBP [Time frame: Baseline to Week8]

Eligibility criteria

Inclusion criteria

  • Signed informed consent
  • Patients with Essential Hypertension
  • Other inclusions applied

Exclusion criteria

  • Patient with Secondary Hypertension
  • Other exclusions applied

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

South Korea · 1 center
  • Gangnam CHA Medical Center — Seoul

Identifiers

NCT: NCT06441630 · AD-227P3

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗